文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

肌肉骨骼疾病合并高血压、心力衰竭或慢性肾脏病患者中处方非甾体抗炎药的使用频率与关联

Frequency and Associations of Prescription Nonsteroidal Anti-inflammatory Drug Use Among Patients With a Musculoskeletal Disorder and Hypertension, Heart Failure, or Chronic Kidney Disease.
PubMed 文献 · JAMA Intern Med · 2018-01-01
一句话结论在合并高血压、心衰或慢性肾脏病的老年患者中,初级保健处方非甾体抗炎药虽常见(9.3%就诊后使用),但未与短期安全相关结局风险增加相关。

这项回顾性队列研究利用加拿大安大略省行政索赔数据库,纳入2012年4月1日至2016年3月31日期间65岁及以上、有高血压、心力衰竭或慢性肾脏病病史的患者,分析肌肉骨骼疾病相关初级保健就诊后7天内处方非甾体抗炎药的使用情况。共识别2,415,291次就诊(814,049名患者),9.3%的就诊后使用了处方非甾体抗炎药,医生层面处方率中位数为11.0%(四分位距6.7%-16.7%)。在35,552对倾向评分匹配的患者中,暴露组与非暴露组的心脏并发症(0.8% vs 0.8%)、肾脏并发症(0.1% vs 0.1%)和死亡(0.1% vs 0.1%)发生率相似。心血管和肾脏安全相关结局合计在暴露组为0.9%、非暴露组为0.8%,绝对风险降低0.0003(95%CI -0.001至0.002,P=0.74),无统计学差异。

要点

  • 在合并高血压、心衰或慢性肾脏病的老年患者中,9.3%的肌肉骨骼疾病初级保健就诊后7天内使用了处方非甾体抗炎药。
  • 医生层面处方率中位数为11.0%(四分位距6.7%-16.7%),存在广泛差异。
  • 倾向评分匹配的35,552对患者中,暴露组与非暴露组心脏并发症(0.8% vs 0.8%)、肾脏并发症(0.1% vs 0.1%)和死亡(0.1% vs 0.1%)发生率相似。
  • 心血管和肾脏安全相关结局合计:暴露组0.9% vs 非暴露组0.8%,绝对风险降低0.0003(95%CI -0.001至0.002,P=0.74),未达统计学显著。
  • 尽管国际肾脏病学会建议避免在这些患者中使用非甾体抗炎药,但本研究中短期安全相关结局未见增加。

适用人群与场景

  • 65岁及以上、有高血压、心力衰竭或慢性肾脏病病史的患者,因肌肉骨骼疾病在初级保健就诊。
  • 研究地点为加拿大安大略省,时间范围为2012年4月1日至2016年3月31日。

研究设计与关键结果

  • 研究类型:回顾性队列研究,链接行政索赔数据库。
  • 样本量:2,415,291次肌肉骨骼相关初级保健就诊,涉及814,049名老年患者(平均年龄75.3岁,标准差4.0;女性61.1%)。
  • 暴露定义:就诊后7天内至少有一次安大略省药物福利计划处方非甾体抗炎药配药索赔。
  • 主要结果:9.3%(224,825次)的就诊后使用了处方非甾体抗炎药;7365名初级保健医生的医生层面处方率中位数为11.0%(四分位距6.7%-16.7%)。
  • 匹配分析:35,552对倾向评分匹配患者中,心脏并发症发生率暴露组0.8%(288例)vs 非暴露组0.8%(279例);肾脏并发症0.1%(34例)vs 0.1%(33例);死亡0.1%(27例)vs 0.1%(30例)。
  • 心血管和肾脏安全相关结局合计:暴露组0.9%(308例)vs 非暴露组0.8%(300例),绝对风险降低0.0003(95%CI -0.001至0.002;P=0.74)。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 国际肾脏病学会建议避免在高血压、心力衰竭或慢性肾脏病患者中使用非甾体抗炎药;本研究中初级保健处方非甾体抗炎药在高风险患者中常见,但未与短期安全相关结局风险增加相关。
  • 研究结果提示,在这一老年高风险人群中,短期处方非甾体抗炎药与心脏并发症、肾脏并发症或死亡风险增加无关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: International nephrology societies advise against nonsteroidal anti-inflammatory drug (NSAID) use in patients with hypertension, heart failure, or chronic kidney disease (CKD); however, recent studies have not investigated the frequency or associations of use in these patients.

OBJECTIVES: To estimate the frequency of and variation in prescription NSAID use among high-risk patients, to identify characteristics associated with prescription NSAID use, and to investigate whether use is associated with short-term, safety-related outcomes.

DESIGN, SETTING, AND PARTICIPANTS: In this retrospective cohort study, administrative claims databases were linked to create a cohort of primary care visits for a musculoskeletal disorder involving patients 65 years and older with a history of hypertension, heart failure, or CKD between April 1, 2012, and March 31, 2016, in Ontario, Canada.

EXPOSURE: Prescription NSAID use was defined as at least 1 patient-level Ontario Drug Benefit claim for a prescription NSAID dispensing within 7 days after a visit.

MAIN OUTCOMES AND MEASURES: Multiple cardiovascular and renal safety-related outcomes were observed between 8 and 37 days after each visit, including cardiac complications (any emergency department visit or hospitalization for cardiovascular disease), renal complications (any hospitalization for hyperkalemia, acute kidney injury, or dialysis), and death.

RESULTS: The study identified 2 415 291 musculoskeletal-related primary care visits by 814 049 older adults (mean [SD] age, 75.3 [4.0] years; 61.1% female) with hypertension, heart failure, or CKD, of which 224 825 (9.3%) were followed by prescription NSAID use. The median physician-level prescribing rate was 11.0% (interquartile range, 6.7%-16.7%) among 7365 primary care physicians. Within a sample of 35 552 matched patient pairs, each consisting of an exposed and nonexposed patient matched on the logit of their propensity score for prescription NSAID use (exposure), the study found similar rates of cardiac complications (288 [0.8%] vs 279 [0.8%]), renal complications (34 [0.1%] vs 33 [0.1%]), and death (27 [0.1%] vs 30 [0.1%]). For cardiovascular and renal-safety related outcomes, there was no difference between exposed patients (308 [0.9%]) and nonexposed patients (300 [0.8%]) (absolute risk reduction, 0.0003; 95% CI, -0.001 to 0.002; P = .74).

CONCLUSIONS AND RELEVANCE: While prescription NSAID use in primary care was frequent among high-risk patients, with widespread physician-level variation, use was not associated with increased risk of short-term, safety-related outcomes.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Bouck Z, Mecredy GC, Ivers NM, et al. Frequency and Associations of Prescription Nonsteroidal Anti-inflammatory Drug Use Among Patients With a Musculoskeletal Disorder and Hypertension, Heart Failure, or Chronic Kidney Disease. JAMA Intern Med. 2018. PMID: 30304456. doi:10.1001/jamainternmed.2018.4273

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。